top of page

Bibliographie

(en cours de rédaction)

 

 

ARTICLES

​

  • Aust S., et Col., “Anxiety during ketamine infusions is associated with negative treatment responses in major depressive disorder”, 2019, Eur Neuropsychopharmacol., 29, 529-538.

  • Austin J.H., “Zen and the brain: Mutually illuminating topics”, 2013, Frontiers in Psychology, 4, ArticleN°784.

  • Badiner A., Gray A. (Edited by), “Zig Zag Zen-Boudhism and Psychedelics”, Chronicle Books, 2002.

  • Barone W, Beck J, Mitsunaga-Whitten M, Perl P. “Perceived benefits of MDMA-assisted psychotherapybeyond symptom reduction: qualitative follow-up study of a clinical trial for individuals with treatment-resistant PTSD”. J Psychoactive Drugs. (2019) 51:199–208. doi: 10.1080/02791072.2019.1580805

  • Barone W., et Col., “Facing death, returning to life: A quantitative analysis of MDMA-assisted therapy foranxiety associated with life-threatening illness”, 2022, Frontiers in Psychiatry, 13: 944849.

  • Barrett FS, Johnson MJ, Griffiths RR (2015) Validation of the revised mystical experiences questionnairein experimental sessions with psilocybin 

  • F.S. Barrett, M.P. Bradstreet, J.S. Leoutsakos, M.W. Johnson, R.R. Griffiths, “The challenging experiencequestionnaire: Characterization of challenging experiences with psilocybin mushrooms”, Journal of Psychopharmacology, 30 (12) (2016), pp. 1279-1295, 10.1177/0269881116678781

  • Barrett, F. S., & Griffiths, R. R. (2017). Classic hallucinogens and mystical experiences: Phenomenology and neural correlates. Behavioral Neurobiology of Psychedelic Drugs, 393–430  - https://doi.org/10.1007/7854_2017_474

  • Barrett, F. S., Doss, M. K., Sepeda, N. D., Pekar, J. J., & Griffiths, R. R. (2020). “Emotions and brain function are altered up to one month after a single high dose of psilocybin”. Scientific Reports, 10, 2214 https://doi.org/10.1038/s41598-020-59282-y.

  • Belser AB, Agin-Liebes G, Swift TC, Terrana S, Devenot N, Friedman H, et al. “Patient experiences of psilocybin-assisted psychotherapy: an interpretative phenomenological analysis”. J Humanist Psychol. (2017), 57, 4,354–388. doi: 10.1177/0022167817706884

  • Bogenschutz MP, Pommy JM (2012) Therapeutic mechanisms of classic halluciongens in the treatment of addictions: from indirect evidence to testable hypotheses. Drug Test Anal 4(543– 555):543

  • Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J., “Psilocybin-assisted treatment for alcohol dependence: A proof-of-concept study”, 2015, Journal of Psychopharmacology, 29, 3, 289–299. https://doi.org/10.1177/026988111456514

  • Bogenschutz MP, Johnson MW (2016) Classic hallucinogens in the treatment of addictions. Prog Neuro-psychoph 64:250–258.

  • T.M. Carbonaro, M.P. Bradstreet, F.S. Barrett, K.A. MacLean, R. Jesse, M.W. Johnson, R.R. Griffiths, “Survey study of challenging experiences after ingesting psilocybin mushrooms: Acute and enduring positive and negative consequences”, Journal of Psychopharmacology, 30 (12) (2016), pp. 1268-1278, 10.1177/0269881116662634

  • Carhart-Harris, RL et al. (2012). Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proceedings of the National Academy of Sciences of the United States of America, 109 (6): 2138-2143

  • Carhart-Harris, RL et al. (2016), “Neural correlates of the LSD experience revealed by multimodal neuroimaging”, Proceedings of the National Academy of Sciences of the United States of America (PNAS Early editions), doi: 10.1073/pnas. 1518377113.

  • Carhart-Harris RL, Bolstridge M, Rucker J, Day CMJ, Erritzoe D, Kaelen M, Bloomfield M, Rickard JA, Forbes B, Feilding A, Taylor D, Pilling S, Curran HV, Nutt DJ, “Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study”, Lancet Psychiatry [Online], 2016b, 3, 7, 619-627.

  • R.L. Carhart-Harris, M. Kaelen, M. Bolstridge, T.M. Williams, L.T. Williams, R. Underwood, D.J. Nutt, “The paradoxical psychological effects of lysergic acid diethylamide (LSD)”, Psychological Medicine, 46 (7) (2016c), pp. 1379-1390, 10.1017/S0033291715002901

  • Carhart-Harris, R. L., Roseman, L., Bolstridge, M., Demetriou, L., Pannekoek, J. N., Wall, M. B., et al. (2017), “Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms”, Scientific Reports, 7, 1, 1–11. http://doi.org/10.1038/s41598-017-13282-7

  • Carhart-Harris, RL et Col., “The entropic brain- revisited”, Neuropharmacology, 2018, 142, 167-178.

  • Carhart-Harris R. et Col., “Psilocybin with psychological support for treatment-resistant depression: six months follow-up”, 2018b, 235, 399-408.

  • Carhart-Harris R. et Col., “Psychedelics and the essential importance of context”, 2018c, Journal of psychopharmacology, 32, 7, 725-731.

  • Carhart-Harris, R.L. & Friston, K.J.,“REBUS and the Anarchic Brain: Towards a Unified Model of the Brain Action of Psychedelics”, Pharmacological Reviews, 2019, 71, 316-344.

  • Cott, C., & Rock, A., “Phenomenology of N,N-dimethyltryptamine use a thematic analysis”, Journal of Scientific Exploration, 2008, 359–370.

  • Davis, A. K., Barsuglia, J. P., Lancelotta, R., Grant, R. M., & Renn, E., 2018. « The epidemiology of 5- methoxy- N, N-dimethyltryptamine (5-MeO-DMT) use: Benefits, consequences, patterns of use subjective effects, and reasons for consumption”, Journal of Psychopharmacology, 32(7), 779 792.  https://doi.org/10.1177/0269881118769063. 

  • Davis, A., Clifton, J., Weaver, E., Hurwitz, E., Johnson, M., & Griffiths, R., “Survey of entity encounter experiences occasioned by inhaled N,N-dimethyltryptamine Phenomenology, interpretation, and enduring effects”, 2020, Journal of Psychopharmacology, 34, 9, 1008–1020. https://doi.org/10.1177/0269881120916143

  • Davis A., et Col., “Psychological flexibility mediates the relations between acute psychedelic effects and subjective decreases in depression and anxiety”, 2020b, J. Contextual Behav Sci., 15, 39-45.

  • Davis A., et Col., “Effects of psilocybin-assisted therapy for major depressive disorder: A randomized clinical trial”, 2020c, JAMA Psychiatry, online.

  • Ditman K.S. et Col., « Nature and frequency of claims following LSD”, Journal of Nervous and Mental Disease, 1962, 134, 464-474.

  • Dittrich, A. (1998). The standardized psychometric assessment of altered states of consciousness (ASCs) in humans. Pharmacopsychiatry, 31(S 2), 80–84. https://doi.org/10.1055/s_2007-979351

  • Doblin R., “Pahnke’s Good Friday experiment: A long term follow-up and methodological critique”, Journal of Transpersonal Psychology, 1991, 23, 1-28.

  • Forstmann M., et Col., “Lifetime experience with (classic) psychedelics predicts pro-environmental behavior through an increase in nature relatedness”, J. Psychopharmacol., 2017, 31, 975-988.

  • A.W. Frank, “Letting Stories Breathe: A Socio-Narratology”, University of Chicago Press, Chicago (2010).

  • Friston, K.: “The Free-Energy Principle: A Unified Brain Theory?”, Nature Reviews Neuroscience, 2010, 11, 127–138.

  • Gashi L., et Col., “Making “bad trips” good: How users of psychedelics narratively transform challenging trips into valuable experiences”, International Journal of Drug Policy, 2021, Volume 87, 102997. Volume 87, January 2021, 102997

  • Gandy S., “Predictors and potentiators of psychedelic-occasioned mystical experiences”, Journal of Psychedelic Studies, 2022, 6, 1, 31-47

  • Garcia-Romeu, A., Griffiths, R., & Johnson, M., “Psilocybin-occasioned mystical experiences in the treatment of tobacco addiction”, 2015, Current Drug Abuse Reviews, 7, 3, 157–164.

  • Garcia-Romeu A., B. Kersgaard, P.H. Addy, “Clinical applications of hallucinogens: A review”, Experimental and Clinical Psychopharmacology, 24 (4) (2016), pp. 229-268, 10.1037/pha0000084

  • Garcia-Romeu et Col., “Cessation and reduction in alcohol consumption and misuse after psychedelic use », 2019, J. Psychopharmacol., 33, 9, 1088-1101.

  • Garcia-Romeu et Col., “Persisting reductions in cannabis, opioid, and stimulant misuse after naturalisticpsychedelic use: An online survey” 2020, Front Pharmacol, 10, 955.

  • Gasser, P., Kirchner, K., and Passie, T. (2015). LSD-assisted psychotherapy for anxiety associated with a life-threatening disease: a qualitative study of acute and sustained subjective effects. J. Psychopharmacol. 29, 57–68. doi: 10.1177/0269881114555249

  • Goodwin G., et Col., “Single-Dose Psilocybin for a Treatment-Resistant Episode of Major Depression”, N Engl J Med, 2022, 387,1637-1648.

  • Griffiths R., et Col., “Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance”, 2006, Psychopharmacology, 87, 268-283.

  • Griffiths R., et Col., “Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later”, Journal of psychopharmacology, 2008, 22, 621-632.

  • Griffiths RR, Johnson MW, Richards WA, Richards BD, McCann U, Jesse R., “Psilocybin occasioned mystical-type experiences: immediate and persisting dose-related effects”, 2011, Psychopharmacology 218(4):649–665. doi:10.1007/s00213-011-2358-5

  • Griffiths, R. R., Johnson, M. W., Carducci, M. A., Umbricht, A., Richards, W. A., Richards, B. D., Klinedinst, M. A., “Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial”, 2016, Journal of Psychopharmacology, 30, 12, 1181–1197. https://doi.org/10.1177/0269881116675513

  • Griffiths, R. R., Johnson, M. W., Richards, W. A., Richards, B. D., Jesse, R., MacLean, K. A., Barrett, F. S., Cosimano, M. P., and Klinedinst, M. A. , “ Psilocybin-occasioned mystical-type experience in combination with meditation and other spiritual practices produces enduring positive changes in psychological functioning and in trait measures of prosocial attitudes and behaviors”, 2018, Psychopharmacol. 32 (1), 49−69.

  • Griffiths RR, Hurwitz ES, Davis AK, Johnson MW, Jesse R, “Survey of subjective "God encounter experiences": Comparisons among naturally occurring experiences and those occasioned by the classic psychedelics psilocybin, LSD, ayahuasca, or DMT”, 2019, PLoS ONE, 14, 4: e0214377. https://doi.org/10.1371/journal.pone.0214377

  • Grob C., et Col., “Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer”,Archives of general Psychiatry, 2011, 68, 71-78.

  • Grob C., & Grigsby J. (eds.), “Handbook of Medical Hallucinogens”, 2021, The Guilford Press.

  • Grof S., “The use of LSD in psychotherapy”, Journal of Psychedelic Drugs, 1970a, 3, 1, 52-62.

  • Grof S., “LSD psychotherapy and human culture (Part I)”, Journal of the Study of Consciousness, 1970b, 3, 100-18.

  • Grof S., “LSD psychotherapy and human culture (Conclusion)”, Journal of the Study of Consciousness,1971, 4, 167-87.

  • Grof S., “Realms of the Human Consciousness: Observations from LSD research”, 1975, New York: Viking.

  • Grof S., “Perinatal roots of wars, totalitarianism, and revolutions: Observations from LSD research”, Journal of Psychohistory, 1977, 4, 269-308.

  • Haijen, E. C. H. M., et Col., “Predicting responses to psychedelics: a prospective study”, 2018, Front. Pharmacol. 9, 897. doi: 10.3389/fphar.2018.00897


  • Halberstadt A., et Col., “Behavioral Neurobiology of Psychedelic Drugs”, Current Topics in Behavioral


  • Neurosciences, Vol 36, Springer, 2018.


  • Hanegraaf W.J., « New Age Religion and Western Culture. Esotericism in the Mirror of Secular


  • Thought », 1995, University of Utrecht


  • Hayes, S. C., Strosahl, K. D., & Wilson, K. G. (2011). Acceptance and Commitment Therapy. Guilford


  • Publications.


  • Hayes SC, Strosahl KD, & Wilson KG (2012). Acceptance and commitment therapy: The process and practice of

  • mindful change, 2nd ed. New York, NY: Guilford Press


  • Hendricks P., Clark C., et Col., « Hallucinogen use predicts reduced recidivism among substance-

  • involved offenders under community corrections supervision”, Journal of Psychopharmacology, 2014, 28,


  • 62-66.


  • Hendricks P., Thorne C., et Col., “Classic psychedelic use is associated with reduced psychological


  • distress and suicidality in the United States adult population”, Journal of Psychopharmacology, 2015, 29,

  • 280-288.


  • Hendricks, P. S. (2018). “Awe: A putative mechanism underlying the effects of classic psychedelic-

  • assisted psychotherapy”. International Review of Psychiatry, 30(4), 331–342.


  • https://doi.org/10.1080/09540261.2018.1474185.

  • Hoffer A., “A program for the treatment of alcoholism; LSD, malvaria and nicotinic acid”, 1967, In H.


  • Abramson (Ed.), The use of LSD in psychotherapy and alcoholism (pp. 343-406). New York, NY: Bobbs-

  • Merrill.


  • Hood, R. W. (1975). The construction and preliminary validation of a measure of reported mystical


  • experience. Journal for the Scientific Study of Religion, 14(1), 29. https://doi.org/10.2307/1384454


  • Hood, R. W., Morris, R. J., & Watson, P. J. (1993). Further factor analysis of Hood's Mysticism Scale.


  • Psychological Reports, 73(3_suppl.), 1176–1178. https://doi.org/10.2466/pr0.1993.73.3f.1176


  • Hood, Jr., R. W., Ghorbani, N., Watson, P. J., Ghramaleki, A. F., Bing, M. N., Davison, H. K., ...


  • Williamson, W. P. (2001). Dimensions of the Mysticism Scale: Confirming the three‐ factor structure in the


  • United States and Iran. Journal for the Scientific Study of Religion, 40(4), 691–705.

  • https://doi.org/10.1111/0021-8294.00085


  • Hood, R. W., Hill, P. C., & Spilka, B. (2009). The psychology of religion: An empirical approach. Guilford


  • Press.


  • Hood, R. W., & Francis, L. J. (2013). Mystical experience: Conceptualizations, measurement, and


  • correlates. APA Handbook of Psychology, Religion, and Spirituality (Vol 1): Context, Theory, and


  • Research., 391–405. https://doi.org/10.1037/14045-021 (par rapport à HMS à 3 facteurs);


  • Huxley A., “La philosophie éternelle -Philosophia perennis », Editions du Seuil, 1977.


  • Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014). Pilot study of the 5-


  • HT2AR agonist psilocybin in the treatment of tobacco addiction. Journal of Psychopharmacology, 28(11),


  • 983–992. https://doi.org/10.1177/0269881114548296


  • Johnson M., et Col., “Human hallucinogen research: Guidelines for safety”, 2008, Journal of

  • Psychopharmacology, 22, 603-620.


  • Kagan S., “The content of complex psychedelic experiences resulting from inhalation of N,N-

  • dimethyltryptamine” , Journal of Psychedelic Studies, 2023, 6, 3, 222-231.


  • Kettner H., et Col., “From egoism to ecoism: Psychedelics increase nature relatedness in a state-

  • Mediated and context-Dependent manner”, J. Environ. Res. Public Heal., 2019, 16, 1-25.


  • Ko K., et Col., “Psychedelics, Mystical Expérience, and Therapeutic Efficacy : A systematic Review”,


  • Frontiers in Psychiatry, 12 July 2022, Vol. 13.


  • Kolp E., et Col., “Ketamine Psychedelic Psychotherapy : Focus on its Pharmacology,


  • Phenomenology, and Clinical Applications”, 2016, In Wolfson, P., and G. Hartelius, editors, “The


  • ketamine papers”, 2016, Santa Cruz, CA: MAPS.


  • Kometer M., Vollenweider F., « The neurobiology of psychedelic drugs: implications for the treatment of


  • mood disorders”, 2010, Nature Reviews Neuroscience, 11, 642-651.


  • Kreplin U., et Col., “The limited prosocial effects of meditation: A systematic review and meta-analysis”,


  • 2018, Scientific Reports, 8, 1, 2403.


  • Leary T., “The religious experience: Its production and interpretation”, Psychedelic Review, 1964, 1, 3,


  • 324-346.


  • Leary T., et Col., “Reactions to psilocybin administered in a supportive environment”, 1963, Journal of


  • Nervous and Mental Disease, 137, 561-573.


  • Lepow L., et Col., “Critical period plasticity as a framework for psychedelic-assisted psychotherapy”,


  • 2021, Front.Neurosci., 15:710004.


  • Lerner M., Lyvers M., « Values and beliefs of psychedelic drug users: A cross cultural study”, J.


  • Psychoactive Drugs, 2006, 38, 143-147.


  • C. Letheby, P. Gerrans, “Self unbound: Ego dissolution in psychedelic experience”, Neuroscience of


  • Consciousness, 2017 (1) (2017), 10.1093/nc/nix016


  • Liechti M.E., et Col., « Alterations of consciousness and mystical-type experiences after acute LSD in


  • humans”, 2016, Psychopharmacology, 234, 1499-1510.


  • Liechti, M. E., Dolder, P. C., & Schmid, Y. (2017). “Alterations of consciousness and mystical-type


  • experiences after acute LSD in humans”. Psychopharmacology, 234(9–10), 1499–1510.


  • https://doi.org/10.1007/s00213-016-4453-0.


  • Luberto C., et Col., “A systematic review and meta-analysis of the effects of meditation on empathy,


  • compassion, and prosocial behaviors”, 2018, Mindfulness, 9, 3, 708-724.


  • Lutkajtis, A. (2020). Entity encounters and the therapeutic effect of the psychedelic mystical experience.


  • J. Psychedelic Stud. 4, 171–178. doi: 10.1556/2054.2020.00143


  • Ly, C., Greb, A. C., Cameron, L. P., Wong, J. M., Barragan, E. V., Wilson, P. C., et al. (2018).


  • Psychedelics Promote Structural and Functional Neural Plasticity. CellReports, 23(11), 3170– 3182.


  • http://doi.org/10.1016/j.celrep.2018.05.022


  • Lyke, J. (2019). “DMT and Entities: Not Everyone Gets Machine Elves” | Jennifer A. Lyke - YouTube.

  • Available at: https://www.youtube.com/ watch?v=bWTT4778IIQ (Accessed: August 4, 2020).


  • Michael Lifshitz, Eli Sheiner, and Laurence J. Kirmayer, “ Cultural Neurophenomenology of Psychedelic


  • Thought: Guiding the “Unconstrained” Mind Through Ritual Context”, The Oxford Handbook of


  • Spontaneous Thought: Mind-Wandering, Creativity, and Dreaming Edited by Kalina Christoff and Kieran


  • C.R. Fox Print Publication Date: May 2018 Subject: Psychology, Cognitive Neuroscience Online


  • Publication Date: Apr 2018 DOI: 10.1093/oxfordhb/9780190464745.013.4


  • MacLean KA, Leoutsakos JM, Johnson MW, Griffiths RR (2012) Factor analysis of the mystical


  • experience questionnaire: a study of experiences occasioned by the hallucinogen psilocybin. J Sci Study


  • Relig 51(4):721–737. doi:10.1111/j.1468-5906.2012.01685.x


  • Majić, T., Schmidt, T. T., & Gallinat, J. (2015). Peak experiences and the afterglow phenomenon: When


  • and how do therapeutic effects of hallucinogens depend on psychedelic experiences? Journal of


  • Psychopharmacology, 29(3), 241–253. https://doi.org/10.1177/0269881114568040


  • Mathai D., et Col., « Toward Synergies of Ketamine and Psychotherapy”, Front. Psychol., 2022, Volume

  • 13, Article 868103.


  • Merkur D., “The ecstatic imagination-Psychedelic experiences and the psychoanalysis of self-

  • actualization”, State University of New York Press, 1998.


  • Michael P, Luke D and Robinson O (2021) “An Encounter With the Other: A Thematic and Content


  • Analysis of DMT Experiences From a Naturalistic Field Study”. Front. Psychol. 12:720717. doi:

  • 10.3389/fpsyg.2021.720717


  • Mitchell J. & col.: “MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-

  • controlled phase 3 trial”. Nature Medicine; 2023-09. https://doi.org/10.1038/s41591-023-02565-4.

  • ​


  • Nikolaidis, A., et Col. “Subtypes of the psychedelic experience have reproducible and predictable effects


  • on depression and anxiety symptoms”, J Affect Disorders , 2023, Mar 1, 324, 239-249,


  • doi.org/10.1016/j.jad.2022.12.042


  • Noorani T, Garcia-Romeu A, Swift TC, Griffiths RR, & Johnson MW (2018). Psychedelic therapy for


  • smoking cessation: Qualitative analysis of participant accounts. Journal of Psychopharmacology, 32,


  • 756–769. [PubMed: 29938565]


  • Olson D., “The Subjective Effects of Psychedelics may not be necessary for their enduring therapeutic


  • effects”, ACS Pharmacol. Transl. Sci., 2021, 4, 563-567.


  • Pahnke WN (1963) Drugs and mysticism: an analysis of the relationship between psychedelic drugs and


  • the mystical consciousness. Harvard University Press, Cambridge, MA


  • Pahnke W., « Drugs and mysticism”, International Journal of Parapsychology, 1966, 8, 295-313.


  • Pahnke WN (1967) LSD and religious experience. In: DeBold RC, Leaf RC (eds) LSD man & society.


  • Wesleyan University Press, Middletown, CT Pahnke WN (1969) Psychedelic drugs and mystical


  • experience. Int Psychiatry Clin 5:149–162.


  • Paloutzian R.F. & Park C.L. (Eds.), “Handbook of the psychology of religion and spirituality”, 2013, New


  • York; Guilford Press.


  • Preller, K. H., & Vollenweider, F. X. (2016). Phenomenology, Structure, and Dynamic of Psychedelic


  • States. Behavioral Neurobiology of Psychedelic Drugs, 221–256. https://doi.org/10.1007/7854_2016_45


  • Raison CL, et al. “Single-Dose Psilocybin Treatment for Major Depressive Disorder: A Randomized

  • Clinical Trial”. JAMA. 2023 Sep 5;330, 9, 843-853. doi: 10.1001/jama.2023.14530.


  • Richards WA, Rhead JC, DiLeo FB, Yensen R, Kurland AA (1977) The peak experience variable in DPT-

  • assisted psychotherapy with cancer patients. J Psychedelic Drugs 9:1–10


  • Riffard M.-O., “Extraordinaire Conscience- Experiences de conscience élargie », Ideo Edition 2023.


  • Roseman L., et Col., “Quality of acute psychedelic experience predicts therapeutic efficacy of psilocybin

  • for treatment-resistant depression”, 2018, Front Pharmacol., 8, 974.


  • Roseman L, Ron Y, Saca A, Ginsberg N, Luan L, Karkabi N, Doblin R and Carhart-Harris R (2021)


  • “Relational Processes in Ayahuasca Groups of Palestinians and Israelis”. Front. Pharmacol. 12:607529.


  • doi: 10.3389/fphar.2021.607529


  • Ross, S., Bossis, A., Guss, J., Agin-Liebes, G., Malone, T., Cohen, B., ... Schmidt, B. L. (2016). Rapid


  • and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients


  • with life-threatening cancer: A randomized controlled trial. Journal of Psychopharmacology, 30(12), 1165–


  • 1180. https://doi.org/10.1177/0269881116675512


  • Russ S. & Eliott M., “Antecedents of mystical experience and dread in intensive meditation”, 2017,


  • Psychology of Consciousness: Theory, Research, and Practice, 4, 1, 38-53.


  • Russ, S. L., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. S. (2019a). “Replication and extension of a


  • model predicting response to psilocybin”. Psychopharmacology, 236, 3221–3230.


  • https://doi.org/10.1007/s00213-019-05279-z.


  • Russ, S. L., Carhart-Harris, R. L., Maruyama, G., & Elliott, M. S. (2019b). “States and traits related to the


  • quality and consequences of psychedelic experiences”. Psychology of Consciousness: Theory,


  • Research, and Practice, 6, 1. https://doi.org/10.1037/cns0000169


  • Schultes RE, Hofmann A, Rätsch C (2001) Plants of the Gods: their sacred, healing, and Hallucinogenic


  • powers. Healing Arts Press.


  • Sepeda, N. D., Clifton, J. M., Doyle, L. Y., Lancelotta, R., Griffiths, R. R., & Davis, A. K. (2020). Inhaled 5-


  • methoxy-N,N-dimethyltryptamine: Supportive context associated with positive acute and enduring effects.


  • Journal of Psychedelic Studies, 4(3), 114–122. https://doi.org/10.1556/2054.2019.033.


  • Sergent B., “Le Dieu fou-Essai sur les origines de Shiva et Dionysos », Les Belles Lettres, 2020.


  • Shanon B., “The antipodes of the mind: Charting the phenomenology of the Ayahuasca experience”,


  • Oxford University Press, 2002.


  • Silverman J., “Shamans and acute schizophrenia”, American Anthropologist, 1967, T. LXIX, n°1, février.


  • Smigielski, L., Kometer, M., Scheidegger, M., Krähenmann, R., Huber, T., & Vollenweider, F. X. (2019).


  • Characterization and prediction of acute and sustained response to psychedelic psilocybin in a


  • mindfulness group retreat. Scientific Reports, 9, 1–13. https://doi.org/10.1038/s41598-019-50612-3


  • Smith H. Do Drugs Have Religious Import? The Journal of Philosophy. 1964; 61(18): 517–530.

  • Smith H. Cleansing the doors of perception. Tarcher/Putnam: New York: 2000.


  • Soler J. et Col., “Exploring the therapeutic potential of ayahuasca: Acute intake increases mindfulness-

  • related capacities”, 2016, Psychopharmacology, 233, 5, 823-829.


  • Soler J. et Col., “Four weekly ayahuasca sessions lead to increases in “acceptance” capacities: A


  • comparison study with a standard 8-week mindfulness training program”, 2018, Frontiers in


  • Pharmacology, 9; Article N° 224.


  • Stace WT. Mysticism and philosophy. London: Macmillan Press; 1960.


  • Strassman R.J., “Adverse reactions to psychedelic drugs. A review of the literature”, Journal of Nervous

  • and Mental Disease, 172 (10) (1984), pp. 577-595, 10.1097/00005053-198410000-00001


  • Strassman, R. J., Qualls, C. R., Uhlenhuth, E. H., & Kellner, R. (1994). Dose-response study of N,N-

  • dimethyltryptamine in humans. II. Subjective effects and preliminary results of a new rating scale.


  • Archives of general psychiatry, 51(2), 98–108. https://doi.org/10.1001/archpsyc.1994.03950020022002

  • ​

  •  


  • https://doi.org/10.1093/acprof:oso/9780195165319.003.0003

  • Studerus, E., Gamma, A., & Vollenweider, F. X. (2010). Psychometric evaluation of the Altered States of Consciousness Rating Scale (OAV). PLoS ONE, 5(8). https://doi.org/10.1371/journal.pone.0012412

  • Studerus, E., Gamma, A., Kometer, M., & Vollenweider, F. X. , “Prediction of psilocybin response in healthy volunteers”, 2012, Plos One, 7, 2, e30800. https://doi.org/10.1371/journal.pone.0030800

  • Swift TC, Belser AB, Agin-Liebes G, Devenot N, Terrana S, Friedman HL, et al. “Cancer at the dinnertable: experiences of psilocybin-assisted psychotherapy for the treatment of cancer-related distress”. 2017, J Humanist Psychol., 57, 488– 519. doi: 10.1177/0022167817715966

  • Timmermann C., et Col., “Psychedelic alter metaphysical beliefs”, Scientific Reports, 23 novembre 2021, 11, 22166.

  • T. Turner, F. Measham, “Into the woods: Contextualising atypical intoxication by young adults in music festivals and nightlife tourist resorts”, Young Adult Drinking Styles, Springer (2019), pp. 87-114.

  • Turton S., Nutt D., Carhart-Harris R., “A qualitative report on the subjective experience of intravenouspsilocybin administered in an FMRI environment”, Current Drug Abuse Reviews, 2014, 7, 117-127.

  • Uthaug, M. V. et Col., « Sub-acute and long-term effects of ayahuasca on affect and cognitive thinking style and their association with ego dissolution”, 2018, Psychopharmacology, 235, 10, 2979-2989.

  • Uthaug, M. V., Lancelotta, R., van Oorsouw, K., Kuypers, K. P. C., Mason, N., Rak, J., et al., “A single inhalation of vapor from dried toad secretion containing 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) in a naturalistic setting is related to sustained enhancement of satisfaction with life, mindfulness- related capacities, and a decrement of psychopathological symptoms”. 2019, Psychopharmacology (Berl)., 236(9), 2653–2666. https://doi.org/10.1007/s00213-019-05236-w.

  • Watts, R., Day, C., Krzanowski, J., Nutt, D., and Carhart-Harris, R. (2017). Patients’ accounts of increased “connectedness” and “acceptance” after psilocybin for treatment-resistant depression. J. Humanist. Psychol. 57, 5, 520–564. doi: 10.1177/0022167817709585

  • Watts, R. (2021). “Psilocybin for depression: The ACE model manual”.https://doi.org/10.31234/osf.io/5x2bu.

  • Watts, R., & Luoma, J. B. (2020). “The use of the psychological flexibility model to support psychedelic assisted therapy”. Journal of Contextual Behavioral Science, 15, 92–102. https://doi.org/10.1016/j.jcbs.2019.12.004

  • Weiss H., Johanson G., Lorena M. (Editors), « Hakomi Mindfulness-Centered Somatic Psychotherapy”, 2015, W.W. Norton & Company.

  • Wolfson PE, Andries J, Feduccia AA, Jerome L, Wang J, Williams E, et al. “MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study”. Sci Rep. (2020) 10:20442. doi: 10.1038/s41598-020-75706-1

  • Yaden D., et Col., « Of Roots and Fruits; A comparison of Psychedelic and Nonpsychedelic Mystical Experiences”, Journal of Humanistic Psychology, 2017, 57, 4, 338-353.

  • Yaden D., Griffiths R., “The Subjective Effects of Psychedelics are necessary for their enduring therapeutic effects”, ACS Pharmacol. Transl. Sci., 2021, 4, 568-572.

​

LIVRES

​​

  • Champagne C., et Col., “Psychologie transpersonnelle et états modifiés de conscience », Enrick.b. Editions, 2021.

  • Cholet B., “Les parasites énergétiques- De la médecine chamanique à la libération spirituelle. Tome 1», 2023, Editions De tout & du Tout.

  • Ferrer J., “Revisioning Transpersonal Theory: A Participatory Vision of Human Spirituality”, State University of New York Press, 2002.

  • Ferrer J., “Participation and the Mystery”, State University of New York Press, 2017.

  • Grof S., “Psychologie Transpersonnelle”, 1996, Editions du Rocher.

  • Grof S., Grof C., “Spiritual emergency: When personal transformation becomes a crisis”, 1989, Los Angeles: Jeremy P. Tarcher.

  • Grof C., Grof S., “ The stormy search for the Self: A guide to personal growth through transformational crisis”, 1990, Los Angeles: Jeremy P. Tarcher.

  • Möckel C., « Voyage en conscience vers la guérison-Fondamentaux de la thérapie psycholytique », édition Solanacée, 2021.

  • Buzzell, L., & Chalquist, C. (2009). “Ecotherapy: Healing with nature in mind”. San Francisco, CA: Sierra Club Books

  • Campbell J., “Le héros aux mille et un visages », Editions Oxus, 2010.

  • Campbell J., “Des mythes pour se construire », Editions Oxus, 2011.

  • Artru E, Rabeyron T., “Psychédéliques, psychothérapie et symbolisation : une revue de la littérature dansle champ de la dépression », L’Evolution Psychiatrique, 2021, 86, 3, 591-616.

  • Assagioli R., « Psychosynthèse : principes et techniques », 1997 (1965), Desclée de Brouwer.

  • Schillinger S., "La Sagesse Interdite", 2023, Editions Véga.

  • Chambon O., Schillinger S., "Psychédéliques : entre science et spiritualité", 2024, Editions Trédaniel.

  • Chambon O. (sous la direction de), "Thérapies Psychédéliques, les Experts témoignent", 2022, Editions Trédaniel.

  • Watts A., « Amour et connaissance », 2022, éditions Almora.

  • Strassman, R., “DMT: The spirit molecule”, Park Street Press, 2001.

  • Strassman, R. (2005). “Hallucinogens. Mind-Altering Drugs”, 49–85.

​​

bottom of page